Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET
Company Participants
Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis
Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer
George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer
Marion McCourt - Executive Vice President, Commercial
Chris Fenimore - Senior Vice President, Finance and Chief Financial Officer
Conference Call Participants
Tyler Van Buren - TD Cowen
Evan Seigerman - BMO Capital Markets
Brian Abrahams - RBC Capital Markets
Cory Kasimov - Evercore ISI
Christopher Raymond - Piper Sandler
Katherine Wang - Jefferies
Chris Schott - JPMorgan
Tim Anderson - Wolfe Research
David Risinger - Leerink Partners
Salveen Richter - Goldman Sachs
Carter Gould - Barclays
Mohit Bansal - Wells Fargo
Operator
Welcome to the Regeneron Pharmaceuticals Second Quarter 2024 Earnings Conference Call. My name is Shannon and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded.
I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.
Ryan Crowe
Thank you, Shannon. Good morning, good afternoon and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our Second Quarter 2024 Earnings Conference Call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after the call ends.
Joining me on today's call are Dr. Leonard Schleifer, Board Co-Chair, Co-Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Board Co-Chair Co-Founder, President and Chief Scientific Officer; Marion McCourt, Executive Vice President of Commercial; and Chris Fenimore, Senior Vice President and Chief Financial Officer.
After our prepared remarks, the remaining time will be available for your questions. We anticipate today's call will last approximately 60 minutes. I would like to remind you that remarks made on today's call may include forward-looking statements about Regeneron.
Such statements may include, but are not limited to, those related to Regeneron and its products and business, financial forecast and guidance, development programs and related anticipated milestones, collaborations, finances, regulatory matters, payer coverage and reimbursement issues, intellectual property, pending litigation and other proceedings and competition. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement.